Shilpa Medicare, via its wholly owned subsidiary, Shilpa Biologicals (SBPL), has entered into a definitive agreement with Cadila Healthcare (CHL) for production-supply of the ZyCov-D vaccine drug substance from its integrated Biologics R&D cum Manufacturing center at Dharwad, Karnataka.
The targeted production of the ZyCoV-D vaccine from this facility will be mutually agreed upon by both parties.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
